Physician profile
Thomas B Atkinson
NPI 1417942020
$2,370.46
in general payments reported to CMS, 2019-2025
27 companies · $18.35 in 2025
The $18.35 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $137 · 2021: $15.89 · 2022: $1,120 · 2023: $934 · 2025: $18.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $480.20 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $388.05 | 2021-2023 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $221.33 | 2019-2023 | Farxiga |
| Pfizer INC. | $209.17 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.01 | 2022-2023 | |
| Lilly USA, LLC | $110.18 | 2019-2023 | Mounjaro, Trulicity, Basaglar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.02 | 2022-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $86.46 | 2019-2023 | Xarelto |
| Mayne Pharma Commercial LLC | $71.80 | 2023 | |
| Astellas Pharma US INC | $66.15 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $64.44 | 2022 | |
| Currax Pharmaceuticals LLC | $50.87 | 2022-2023 | Contrave |
| Glaxosmithkline, LLC. | $49.20 | 2022-2023 | Trelegy Ellipta |
| Exeltis, USA INC. | $46.77 | 2022-2023 | Slynd |
| Exact Sciences Corporation | $43.63 | 2023 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.17 | 2022-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $38.75 | 2022 | |
| Therapeuticsmd, INC. | $33.96 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $25.59 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.20 | 2022 | |
| Organon LLC | $19.98 | 2023 | Nexplanon |
| Inspire Medical Systems, INC. | $18.35 | 2025 | Inspire |
| Agile Therapeutics, INC. | $17.58 | 2023 | Twirla |
| Amgen INC. | $15.35 | 2022 | |
| Dexcom, INC. | $13.78 | 2022 | |
| Allergan, INC. | $11.28 | 2019 | |
| Merck Sharp & Dohme LLC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.